𝔖 Bobbio Scriptorium

✦ LIBER ✦

P-840 Epoetin beta 30,000 IU once weekly for the treatment ofanaemia in patients with lung cancer receiving chemotherapy: A prospective survey of the efficacy and timing of treatment in a clinical setting

✍ Scribed by Pirker, R.; Lehnert, M.; Minar, W.

Book ID: 122463624
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 270 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(05)81333-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1347 PUBLICATION Breast cancer-Anaemia a

1347 PUBLICATION Breast cancer-Anaemia and the Value of Erythropoietin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30,000 IU once weekly in patients with metastatic breast cancer receiving chemotherapy

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB